MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
MANNKIND CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.09+0.05 (+1.64%)
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
MANNKIND CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | $216.52M | $178.56M | $126.05M | $81.07M | $39.44M | – | – | – | – | – | 62.0% | +21.3% |
| Royalties | $128.12M | $102.34M | $71.98M | $15.60M | – | – | – | – | – | – | 36.7% | +25.2% |
| Sale of product | $114.14M | $82.33M | $74.03M | $56.25M | $39.17M | $32.32M | $25.30M | $17.28M | $9.19M | $1.90M | 32.7% | +38.6% |
| Collaborations and services | $106.71M | $100.84M | $52.95M | $27.92M | $36.27M | $32.82M | $37.73M | $10.58M | $250.00K | $171.97M | 30.6% | +5.8% |
| Services | $4.33M | $4.61M | $929.00K | $3.10M | $36.01M | $32.82M | – | – | – | – | 1.2% | -6.2% |
| Manufacturing Services | $1.60M | $7.10M | $0 | – | – | – | – | – | – | – | 0.5% | -77.5% |
| Revenue - other | – | – | – | – | – | – | – | – | $2.30M | $898.00K | – | – |
| Bulk insulin sales | – | – | – | – | – | – | – | – | $1.70M | – | – | – |
| Product Sales | – | – | – | $81.07M | $39.44M | $32.32M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mannkind's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.